Therapeutic Targets: Modulation, Inhibition, and Activation
ISBN/ASIN: 9780470587195,9781118185537 | 2012 | English | pdf | 497/497 pages | 3.98 Mb
The Latest Applications For Cellmechanism Research in Drug Discovery
Designed to connect research on cell mechanisms with the drug discovery process, Therapeutic Targets: Modulation, Inhibition, and Activation introduces readers to a range of new concepts and novel approaches to drug screening and therapeutic drug targeting to help inform future avenues of drug research. Highly topical, this accessible edited volume features chapters contributed by respected experts from around the globe.
The book helps postgraduate students and professional scientists working in academia and industry understand the molecular mechanisms of pharmacology, current pharmacological knowledge, and future perspectives in drug discovery, focusing on important biochemical protein targets and drug targeting strategies for specific diseases. Examining the pharmacology of therapeutically undefined targets and their potential applications, it includes chapters on traditional therapeutic targets, including enzymes (phosphodiesterases and proteases), ion channels, and G protein-coupled receptors, as well as more recently identified avenues of exploration, such as lipids, nuclear receptors, gene promoters, and more.
Since different diseases require different targeting techniques, the book also includes dedicated chapters on strategies for investigating Alzheimer's, diabetes, pain, and inflammation treatments. Concluding with a cross-sectional look at new approaches in drug screening, Therapeutic Targets is an invaluable resource for understanding where the next generation of drugs are likely to emerge.
Chapter 1 cAMP?Specific Phosphodiesterases: Modulation, Inhibition, and Activation (pages 1–35): R. T. Cameron and George S. Baillie
Chapter 2 Protease?Activated Receptor 2 (pages 37–61): Qihai Gu and Lu?Yuan Lee
Chapter 3 Voltage?Gated Sodium Channels as Therapeutic Targets (pages 63–122): Joshua S. Wingerd, Irina Vetter and Richard J. Lewis
Chapter 4 Multitarget Drugs for Stabilization of Calcium Cycling and Neuroprotection in Neurodegenerative Diseases and Stroke (pages 123–200): Antonio M. G. de Diego, Silvia Lorrio, Jesus M. Hernandez?Guijo, Luis Gandia and Antonio G. Garcia
Chapter 5 Oligomerization of G?Protein?Coupled Receptors (pages 201–223): Juan F. Lopez?Gimenez and Javier Gonzalez?Maeso
Chapter 6 Sigma 1 Receptor Chaperone: Pharmacology and Therapeutic Perspectives (pages 225–278): Daniel Zamanillo, Enrique Portillo?Salido, Jose Miguel Vela and Luz Romero
Chapter 7 Lipids as New Targets (pages 279–308): Eduardo Dominguez
Chapter 8 Knowledge Base for Nuclear Receptor Drug Discovery (pages 309–326): Albert A. Antolin and Jordi Mestres
Chapter 9 Gene Promoters and Transcription Control Regions as Therapeutic Targets (pages 327–350): Antonio Zorzano, David Sebastian, Jana Sanchez?Wandelmer, Laia Miret and Fernando Albericio
Chapter 10 Roles of Glucagon?Like Peptide and Glucose?Dependent Insolinotropic Polypeptide Hormones in Brain Function and Neurodegeneration (pages 351–373): Christian Holscher
Chapter 11 Exocytotic Machinery as a Target for the Development of New Drugs for Schizophrenia (pages 375–408): Maria Jose Guerrero, Itsaso Hormaeche, Maria Uribarri, Julie Masse and Jose Maria Palacios
Chapter 12 Targeting Epigenetic Abnormalities in the Brain (pages 409–426): Erin Y. Sterner, Lisa E. Kalynchuk and Hector J. Caruncho
Chapter 13 Rodent Models as Tools for Discovering Novel Therapeutic Targets in the Brain: The Case of Epilepsy (pages 427–454): Justin J. Botterill, Axel J. Guskjolen, Lisa E. Kalynchuk and Hector J. Caruncho
Chapter 14 New Approaches Applied to Drug Screening (pages 455–476): Jose Brea and Maria Isabel Loza